You are here: Industry Insights > polyneuropathy

News List

Alnylam receives fast track designation for Vutrisiran to treat polyneuropathy of hATTR amyloidosis pharmaceutical-business-review
April 17, 2020
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vutrisiran.
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) pharmaceutical-business-review
March 30, 2020
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases ...
UK NICE recommends use of Akcea’s Tegsedi for polyneuropathy pharmaceutical-technology
April 22, 2019
The National Institute for Health and Care Excellence (NICE) in the UK has issued positive recommendation for Akcea Therapeutics’ Tegsedi (inotersen) to treat stage 1 or stage 2 polyneuropathy...
Alnylam partners with Medison to offer Onpattro in Israel pharmaceutical-technology
January 23, 2019
US-based Alnylam Pharmaceuticals has signed an exclusive agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel....
Onpattro approved by FDA as first treatment for polyneuropathy pharmaceutical-technology
August 15, 2018
Alnylam Pharmaceuticals has obtained approval from the US Food and Drug Administration (FDA) for Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) in adults with hereditary transthyretin-mediated amyloidosis (hATTR).